Kidswell Bio

Kidswell Bio EPS

The Earnings per Share (EPS) of Kidswell Bio (4584.T) as of Nov 5, 2026 is -8.16 JPY. In the previous year, Earnings per Share (EPS) was -0.43 JPY — a change of 1,814.37% (lower).

EPS

-8.16JPY

YoY

1,814.37%

Last updated:

Earnings per Share (EPS) of Kidswell Bio is 2026 -8.16 JPY. Earnings per Share (EPS) of Kidswell Bio was 2025 -0.43 JPY. It decreases by 1,814.37% lower compared to the previous year.

The Kidswell Bio EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-17.40 JPY
Jan 1, 2023
-17.61 JPY
Jan 1, 2024
-34.97 JPY
Jan 1, 2025
-0.43 JPY
Jan 1, 2026
-8.16 JPY
Jan 1, 2027 (e)
19.30 JPY
Jan 1, 2028 (e)
29.60 JPY
Jan 1, 2029 (e)
32.70 JPY
The Kidswell Bio EPS history
YEAREPSYoY
est32.70JPY+10.47%
est29.60JPY+53.37%
est19.30JPY-336.56%
-8.16JPY+1,814.37%
-0.43JPY-98.78%
-34.97JPY+98.54%
-17.61JPY+1.19%
-17.40JPY-45.37%
-31.86JPY-87.35%
-251.77JPY+712.88%
-30.97JPY-32.78%
-46.08JPY-28.43%
-64.38JPY+314.74%
-15.52JPY-0.54%
-15.61JPY-74.15%
-60.38JPY+0.91%
-59.84JPY-10.52%
-66.88JPY-3.64%
-69.40JPY+45.49%
-47.70JPY-53.50%
-102.57JPY+95.70%
-52.41JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kidswell Bio Stock analysis

What does Kidswell Bio do? Kidswell Bio Corp develops biopharmaceutical products, focusing on biosimilar filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The company also researches anti-RAMP2 antibodies for cancer and eye diseases, new antibodies, and regenerative medicine using intracardiac stem cells for pediatric heart conditions and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency. Revenue comes from the biosimilar business, new biopharmaceutical business, and new biotechnology business, targeting healthcare providers and medical institutions seeking cost-effective treatments. The biosimilar products include filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The new biopharmaceutical business develops anti-RAMP2 antibodies and new antibodies, while the new biotechnology business focuses on regenerative medicine with stem cell applications. These products are sold to hospitals, clinics, and research institutions requiring advanced biopharmaceutical solutions. Kidswell Bio Corp's revenue streams are derived from the sale of biosimilar products, anti-RAMP2 antibodies, and regenerative medicine solutions. The company targets healthcare providers in oncology, nephrology, ophthalmology, and regenerative medicine sectors. Sales are driven by the demand for affordable alternatives to branded biologics, with a focus on pediatric and chronic disease treatments. Kidswell Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kidswell Bio stock

Earnings per Share (EPS) of Kidswell Bio is -8.16 JPY in 2026.

Earnings per Share (EPS) of Kidswell Bio changed from -0.43 JPY to -8.16 JPY, representing a 1,814.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Kidswell Bio since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Kidswell Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Kidswell Bio